Differential Impact of Concomitant Methotrexate and Glucocorticoids Dosages on Biologics and JAK Inhibitors: The ANSWER Cohort Study
International Journal of Rheumatic Diseases · 2025
DOI: 10.1111/1756-185x.70351 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Rheumatic Diseases, 2025. Verfasst von Kosuke Ebina und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, The University of Osaka Graduate School of Medicine Faculty of Medicine, Suita, Japan. Hauptthemen laut MEDLINE: Methotrexate, Janus Kinase Inhibitors, Glucocorticoids, Arthritis, Rheumatoid. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Ono Pharmaceutical, Sanofi, Eli Lilly Japan.
Abstract (Originalsprache)
Aim
This multicenter retrospective study evaluated the differential impact of concomitant methotrexate (MTX) and glucocorticoids (GCs) administration by dosage on the effectiveness and safety of biological disease‐modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKi) in a real‐world cohort of patients with rheumatoid arthritis, adjusting for clinical backgrounds variables.
Methods
The study included 3751 treatment courses (bDMARD‐ or JAKi‐naïve cases, 48.9%; tumor necrosis factor inhibitors: 1668; tocilizumab [TCZ]: 865; abatacept [ABT]: 825; JAKi: 393). Hazard ratios for treatment retention were calculated using multivariate Cox proportional hazards models, adjusted for potential confounders. Improvement in the clinical disease activity index (ΔCDAI) with each formulation was analyzed using mixed‐effects models for repeated measures, stratified by concomitant MTX and GCs dosages.
Results
Compared to MTX(−), a lower dose of MTX (< 10 mg/week) was associated with significant improvement in ΔCDAI with golimumab (GLM), TCZ, and JAKi and reduced discontinuation due to ineffectiveness of etanercept (ETN). A higher MTX dose (≥ 10 mg/week) demonstrated a similar trend. Compared to GCs(−), a lower dose of GCs (≤ 5 mg/day; prednisolone equivalent) was associated with a diminished ΔCDAI with GLM and an increased discontinuation due to ineffectiveness of ADA and GLM. A higher dose of GCs (> 5 mg/day) was associated with increased discontinuation due to safety with ETN, CZP, and JAKi.
Conclusions
The effects of concomitant MTX and GCs dosages on the effectiveness and safety of biologics and JAKi vary among agents. MTX did not mitigate safety issues, and GCs did not enhance effectiveness of any agents, regardless of dosage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, The University of Osaka Graduate School of Medicine Faculty of Medicine, Suita, Japan.
- Department of Sports Medical Biomechanics, The University of Osaka Graduate School of Medicine Faculty of Medicine, Suita, Japan.
- Department of Respiratory Medicine and Clinical Immunology, The University of Osaka Graduate School of Medicine Faculty of Medicine, Suita, Japan.
- Department of Orthopaedic Surgery, Osaka Minami Medical Center, Kawachi-Nagano, Japan.
- Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Clinical Immunology, School of Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
ORCID-Profile: Kosuke Ebina, Yuki Etani, Yasutaka Okita, Kohei Tsujimoto, Yuichi Maeda, Takaaki Noguchi, Makoto Hirao, Koichi Murata, Takayuki Fujii, Motomu Hashimoto, Tadashi Okano, Takuya Kotani, Koji Nagai, Takaichi Okano, Iku Shirasugi, Ryota Hara, Yonsu Son, Hideki Amuro, Masaki Katayama, Shotaro Tachibana, Shinya Hayashi, Wataru Yamamoto, Atsushi Kumanogoh, Ken Nakata, Seiji Okada, Akira Onishi
Förderung
- Ono Pharmaceutical
- Sanofi
- Eli Lilly Japan
- Janssen Japan
- UCB
- Taisho
- Teijin Healthcare
- AbbVie
Zitieren
APA
Ebina, K., Etani, Y., Okita, Y., Tsujimoto, K., Maeda, Y., Noguchi, T., Hirao, M., Murata, K., Fujii, T., Hashimoto, M., Okano, T., Kotani, T., Nagai, K., Okano, T., Shirasugi, I., Hara, R., Son, Y., Amuro, H., Katayama, M., …, & Onishi, A. (2025). Differential Impact of Concomitant Methotrexate and Glucocorticoids Dosages on Biologics and JAK Inhibitors: The ANSWER Cohort Study. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70351
Vancouver
Ebina K, Etani Y, Okita Y, Tsujimoto K, Maeda Y, Noguchi T, et al. Differential Impact of Concomitant Methotrexate and Glucocorticoids Dosages on Biologics and JAK Inhibitors: The ANSWER Cohort Study. International Journal of Rheumatic Diseases. 2025. doi:10.1111/1756-185x.70351
BibTeX
@article{Ebina2025,
author = {Ebina, Kosuke and Etani, Yuki and Okita, Yasutaka and Tsujimoto, Kohei and Maeda, Yuichi and Noguchi, Takaaki and Hirao, Makoto and Murata, Koichi and Fujii, Takayuki and Hashimoto, Motomu and Okano, Tadashi and Kotani, Takuya and Nagai, Koji and Okano, Takaichi and Shirasugi, Iku and Hara, Ryota and Son, Yonsu and Amuro, Hideki and Katayama, Masaki and Tachibana, Shotaro and Hayashi, Shinya and Yamamoto, Wataru and Kumanogoh, Atsushi and Nakata, Ken and Okada, Seiji and Onishi, Akira},
title = {Differential Impact of Concomitant Methotrexate and Glucocorticoids Dosages on Biologics and JAK Inhibitors: The ANSWER Cohort Study},
journal = {International Journal of Rheumatic Diseases},
year = {2025},
doi = {10.1111/1756-185x.70351}
}
EUVIMED